Is Colossal Biosciences a for-profit company, and how does that align with conservation?

Colossal Biosciences operates as a for-profit biotechnology company developing breakthrough conservation technologies, while the Colossal Foundation operates as its nonprofit arm, deploying these innovations directly to field partners. This dual structure enables Colossal to attract investment capital, bringing new funding streams to conservation rather than competing for traditional conservation dollars. The for-profit model allows Colossal to raise the substantial capital needed to advance expensive de-extinction technologies with applications spanning conservation, agriculture, and human healthcare.

Bringing New Investment to Conservation

  • Global investment in conservation is a small fraction of overall consumer spending; annually, the world spends roughly three times more on soda than on biodiversity protection

  • Colossal addresses this funding gap by attracting investment specifically earmarked for conservation technology innovation. Its dual for-profit and nonprofit structure brings new capital into conservation without diverting resources from existing efforts

  • The Colossal Foundation partners with over 55 conservation organizations to transfer de-extinction technologies directly into field applications

  • The Colossal Species Reintroduction Fund commits at least $250,000 annually to support every phase of species reintroductions, ranging from genetic assessment to post-release monitoring for at-risk species
  • Colossal Foundation has committed $100 million in total funding to deploy breakthrough technology to the front lines of the extinction crisis

Technologies That Serve Multiple Sectors

  • Colossal’s de-extinction technologies, including CRISPR capabilities, require substantial capital investment that the for-profit structure enables

  • The investment and commercialization of these technologies has implications across bioscience, from drug discovery, gene editing, to eliminating disease

  • Colossal’s work on dire wolf de-extinction has direct applications for wolf conservation and genetic rescue of endangered and at-risk species

  • By equipping conservationists with these innovations, Colossal translates scientific progress into tangible outcomes for species preservation—while simultaneously advancing technologies with broad applications in modern medicine.

Deploying Innovation Where It Matters Most

  • Colossal Biosciences has supported over 40 species through technology development and direct field partnerships, including 25+ critically endangered or extinct-in-the-wild species

  • The Colossal Foundation has mobilized $100 million for conservation efforts, with $17.3 million in direct partner investments and $5.5 million supporting frontline species recovery and rewilding projects

  • The integrated for-profit/nonprofit model demonstrates how biotechnology can accelerate conservation outcomes by developing commercially viable technologies with conservation applications

  • This approach brings new ways to invest in conservation while equipping field conservationists with cutting-edge tools to save endangered and at-risk species today